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LETTER TO THE EDITOR
In regard to Minniti et al.: Current status 
and recent advances in resection cavity 
irradiation of brain metastases—roundup 
to cover all angles
Gustavo R. Sarria1 , Christopher P. Cifarelli2, Henning Kahl3 and Frank A. Giordano1* 
Abstract 
We read with great interest the recent review, entitled “Current status and recent advances in resection cavity irradia-
tion of brain metastases”. It is a comprehensive summary of currently available techniques for treatment of post-resec-
tion cavity in patients with this diagnosis. We would like to complement this manuscript by including intraoperative 
techniques as other viable approaches in the management of these patients.
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Letter body
In regard of the recently published review by Minniti et 
al. [1], which summarizes the current evidence on resec-
tion cavity irradiation of brain metastases (BM), we 
would like to provide our insights of other methods for 
this purpose. The development of intraoperative radio-
therapy (IORT) over the past four decades has opened 
a vast spectrum of possible applications for malignancy 
treatment. Since the first published experiences from 
Japan in the early 1980’s on treating gliomas and BM, 
employing an electron-based IORT device (IOERT), 
timely resurgence of this technique has paved its road to 
evolving into a modern therapeutic alternative for BM. In 
addition, a growing body of evidence for intraoperative 
brachytherapy further contributes to widen the therapeu-
tic arsenal in this setting.
Although no large randomized trials are available, both 
historical and current evidence in the management of 
BM with brachytherapy implants support this irradia-
tion method. Reinforcing historical reports from over 
25 years ago [2], a more recent prospective study demon-
strated the feasibility and safety of applying  Cs131 intra-
operatively to the resection cavity in 42 patients carrying 
46 BM, prescribing 80 Gy at 5 mm depth, reaching a local 
control rate of 100% after 1.5 years with no cases of radi-
onecrosis (RN) [3]. Successive retrospective analysis have 
suggested similar results, with a relatively low rate of RN 
[4, 5]. However, evidence from these rather small cohorts 
should be carefully interpreted.
The dawn of IORT is directly related to low-energy 
x-rays (kilovoltage-kV), initially published as early as 
1907 for treatment of abdominal malignancies [6]. 
Modern technology has adapted kV units to portable 
and versatile devices. Their generally low shielding 
requirements turns them of use for in- and outpatient 
management. Under the general principle of high-
conformal dose distribution and healthy tissue sparing, 
this sharp fall-off dose of 50-kV accelerators enables 
concentrating increased doses on a quite well defined 
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target area. Treatment application through a spheri-
cal applicator allows a homogeneous delivery doses in 
a circumferential fashion, providing excellent cover-
age of the entire resection cavity and a steep dose drop 
to approximately 30% of the surface dose at 1  cm [7]. 
Nevertheless, it must be noted that thorough patient 
selection should be performed, in order to determine 
applicability, proximity to organs at risk (OAR) and 
dose to deliver. Furthermore, a final decision might be 
made only during resection, after live assessment under 
direct view.
An early IOERT report with a considerable number 
of patients with BM including 43 metastatic lesions 
treated with a mean 19.9  Gy (18–25) dose prescribed 
at 1-cm depth, resulted in seven patients develop-
ing local failure within 1  year after treatment. Being 
approximately an 84% rate, these results remain compa-
rable to those resection plus whole-brain radiotherapy 
(WBRT) or stereotactic radiosurgery (SRS) approaches 
[8]. Nonetheless, elevated rates of “encephalic atrophy” 
and “dementia” were described, likely due to the large 
healthy-tissue volume exposed to the prescription dose 
[9].
Dosimetric comparisons have determined the fea-
sibility of dose escalation with kilovoltage-IORT (kV-
IORT), confirming a clear benefit in terms of healthy 
tissue sparing [10]. After these considerations, initial 
clinical experiences with kV-IORT have been reported 
during the last decade. A recent multi-institutional ret-
rospective study by our group reported on 54 patients 
who received superficial doses of mostly 20–30  Gy, 
with 1-year local control and overall survival rates of 
88% and 73%, respectively. It is noteworthy to point 
that treatment times varied between 12.1 to 22.3  min, 
according to the applicator diameter [11]. Ongoing 
prospective trials (NCT03226483, NCT04690348) and 
the initiation of an international kV-IORT registry will 
deliver data on the future value of these technologies in 
the treatment of brain metastases.
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